Back to Search Start Over

Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer

Authors :
Yeorae Kim
Ala Aiob
Hyojin Kim
Dong Hoon Suh
Kidong Kim
Yong Beom Kim
Jae Hong No
Source :
Biomedicines, Vol 11, Iss 10, p 2691 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

This study investigated PD-L1 expression in endometrial cancer, its links with prognostic factors, and survival outcomes in 232 patients. Of these, 73 (31.5%) had PD-L1-positive tumors and 159 (68.5%) had PD-L1-negative tumors. PD-L1 expression significantly correlated with adverse prognostic factors. The PD-L1-positive group had higher rates of high-grade tumors (37.0% vs. 19.1%, p = 0.004), deep myometrial invasion (35.6% vs. 24.4%, p = 0.004), lymphovascular space invasion (LVSI) (39.7% vs. 25.6%, p = 0.023), and lymph node metastasis (7.2% vs. 17.1%, p = 0.024) than the PD-L1-negative group. While 5-year progression-free survival (PFS) favored the PD-L1-negative group (94.1% vs. 86.3%), this difference lacked statistical significance (p = 0.139). No significant variations emerged in overall survival (OS) (p = 0.596) or recurrence rates between the groups. Although outcomes lack statistical significance, they suggest a plausible link between PD-L1 and established adverse prognostic factors, such as histological grade, myometrial invasion depth, LVSI, and lymph node metastasis in endometrial cancer. These insights hint at PD-L1’s potential as an informal prognostic indicator, potentially aiding in endometrial cancer patient management.

Details

Language :
English
ISSN :
11102691 and 22279059
Volume :
11
Issue :
10
Database :
Directory of Open Access Journals
Journal :
Biomedicines
Publication Type :
Academic Journal
Accession number :
edsdoj.25475da936764e1d96d341ae406ee460
Document Type :
article
Full Text :
https://doi.org/10.3390/biomedicines11102691